

What is claimed is:

1. A compound which is crystalline carvedilol dihydrogen phosphate hemihydrate.
- 5 2. The compound according to claim 1 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta as shown in Figure 1.
- 10 3. The compound according to claim 2 having characteristic peaks from  $0^{\circ}$  degrees 2-theta ( $2\theta$ ) to  $35^{\circ}$  degrees 2-theta ( $2\theta$ ) at about  $7.0 \pm 0.2$  ( $2\theta$ ),  $11.4 \pm 0.2$  ( $2\theta$ ),  $15.9 \pm 0.2$  ( $2\theta$ ),  $18.8 \pm 0.2$  ( $2\theta$ ),  $20.6 \pm 0.2$  ( $2\theta$ ),  $22.8 \pm 0.2$  ( $2\theta$ ), and  $25.4 \pm 0.2$  ( $2\theta$ ).
- 15 4. The compound according to claim 1 having an infrared spectrum which comprises characteristic absorption bands expressed in wave numbers as shown in Figure 6.
- 20 5. The compound according to claim 1 having a Raman spectrum which comprises characteristic peaks as shown in Figure 3.
6. A compound which is carvedilol dihydrogen phosphate dihydrate.
- 25 7. The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta ( $2\theta$ ) as shown in Figure 9.
- 30 8. The compound according to claim 7 having characteristic peaks from  $0^{\circ}$  degrees 2-theta ( $2\theta$ ) to  $35^{\circ}$  degrees 2-theta ( $2\theta$ ) at about  $6.5 \pm 0.2$  ( $2\theta$ ),  $7.1 \pm 0.2$  ( $2\theta$ ),  $13.5 \pm 0.2$  ( $2\theta$ ),  $14.0 \pm 0.2$  ( $2\theta$ ),  $17.8 \pm 0.2$  ( $2\theta$ ),  $18.9 \pm 0.2$  ( $2\theta$ ), and  $21.0 \pm 0.2$  ( $2\theta$ ).

9. The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta ( $2\theta$ ) as shown in Figure 25.

5

10. The compound according to claim 9 having characteristic peaks from  $0^\circ$  degrees 2-theta ( $2\theta$ ) to  $35^\circ$  degrees 2-theta ( $2\theta$ ) at about  $6.4 \pm 0.2$  ( $2\theta$ ),  $9.6 \pm 0.2$  ( $2\theta$ ),  $16.0 \pm 0.2$  ( $2\theta$ ),  $18.4 \pm 0.2$  ( $2\theta$ ),  $20.7 \pm 0.2$  ( $2\theta$ ), and  $24.5 \pm 0.2$  ( $2\theta$ ).

10

11. A compound which is carvedilol dihydrogen phosphate methanol solvate.

12. The compound according to claim 11 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta ( $2\theta$ ) as shown in Figure 24.

15

13. The compound according to claim 12 having characteristic peaks from  $0^\circ$  degrees 2-theta ( $2\theta$ ) to  $35^\circ$  degrees 2-theta ( $2\theta$ ) at about  $6.9 \pm 0.2$  ( $2\theta$ ),  $7.2 \pm 0.2$  ( $2\theta$ ),  $13.5 \pm 0.2$  ( $2\theta$ ),  $14.1 \pm 0.2$  ( $2\theta$ ),  $17.8 \pm 0.2$  ( $2\theta$ ), and  $34.0 \pm 0.2$  ( $2\theta$ ).

20

14. A compound which is carvedilol dihydrogen phosphate.

15. The compound according to claim 14 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta ( $2\theta$ ) as shown in Figure 28.

25

16. The compound according to claim 15 having characteristic peaks from  $0^\circ$  degrees 2-theta ( $2\theta$ ) to  $35^\circ$  degrees 2-theta ( $2\theta$ ) at about  $13.2 \pm 0.2$  ( $2\theta$ ),  $15.8 \pm 0.2$  ( $2\theta$ ),  $16.3 \pm 0.2$  ( $2\theta$ ),  $21.2 \pm 0.2$  ( $2\theta$ ),  $23.7 \pm 0.2$  ( $2\theta$ ), and  $26.0 \pm 0.2$  ( $2\theta$ ).

30

17. A compound which is carvedilol hydrogen phosphate.
18. The compound according to claim 17 having an x-ray  
5 diffraction pattern which comprises characteristic peaks in degrees two-theta (2 $\theta$ ) as shown in Figure 29.
19. The compound according to claim 18 having characteristic  
peaks from 0° degrees 2-theta (2 $\theta$ ) to 35° degrees 2-theta (2 $\theta$ ) at about 5.5  $\pm$   
10 0.2 (2 $\theta$ ), 12.3  $\pm$  0.2 (2 $\theta$ ), 15.3  $\pm$  0.2 (2 $\theta$ ), 19.5  $\pm$  0.2 (2 $\theta$ ), 21.6  $\pm$  0.2 (2 $\theta$ ), and  
24.9  $\pm$  0.2 (2 $\theta$ ).
20. A pharmaceutical composition comprising the compound  
according to claim 1 and a pharmaceutically acceptable carrier.  
15
21. A pharmaceutical composition comprising the compound  
according to claim 6 and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising the compound  
20 according to claim 14 and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising the compound  
according to claim 17 and a pharmaceutically acceptable carrier.
24. A method of treating hypertension, congestive heart failure  
25 or angina which comprises administering to a subject in need thereof an  
effective amount of the compound according to claim 1.
25. A method of treating hypertension, congestive heart failure  
30 or angina which comprises administering to a subject in need thereof an  
effective amount of the compound according to claim 6.

26. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 14.

5 27. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 17.

10 28. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 20.

15 29. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 21.

20 30. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 22.

31. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 23.